PT  - JOURNAL ARTICLE
AU  - Dambha-Miller, Hajira
AU  - Albasri, Ali
AU  - Hodgson, Sam
AU  - Wilcox, Chris
AU  - Islam, Nazrul
AU  - Khan, Shareen
AU  - Little, Paul
AU  - Griffin, Simon J
TI  - Drug treatments affecting ACE2 in COVID-19 infection: a systematic review protocol
AID  - 10.1101/2020.05.25.20100438
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.25.20100438
4099  - http://medrxiv.org/content/early/2020/05/26/2020.05.25.20100438.short
4100  - http://medrxiv.org/content/early/2020/05/26/2020.05.25.20100438.full
AB  - Background The SARS-CoV-2 virus causing COVID-19 binds human angiotensin-converting enzyme 2 (ACE2) receptors in human tissues. ACE2 expression may be associated with COVID-19 infection and mortality rates. Routinely prescribed drugs which up- or down-regulate ACE2 expression are therefore of critical research interest as agents which might promote or reduce risk of COVID-19 infection in a susceptible population.Aim To review evidence on routinely prescribed drug treatments in the UK that could up- or down-regulate ACE2 and potentially affect COVID-19 infection.Design and setting Systematic review of studies published in MEDLINE, EMBASE, CINAHL, the Cochrane Library and Web of Science from inception to April 1st 2020.Method A systematic review will be conducted in line with PRISMA guidelines. Inclusion criteria will be: i) assess effect of drug exposure on ACE2 level; ii) drug is included in British National Formulary (BNF) and therefore available to prescribe in UK; iii) a control, placebo or sham group is included as comparator. Exclusion criteria will be: i) ACE2 measurement in utero; ii) ACE2 measurement in children under 18 years; iii) drug not in BNF; iv) review article. Quality will be assessed using the Cochrane risk of bias tool for human studies, and the SYRCLE risk of bias tool for animal studies.Results Data will be reported in summary tables and narrative synthesis.Conclusion This systematic review will identify drug therapies which may increase or decrease ACE2 expression. This might identify medications increasing risk of COVID-19 transmission, or as targets for intervention in mitigating transmission.Competing Interest StatementCompeting interests: Prof Griffin reports grants from Wellcome Trust, Medical Research Council, NIHR, NIHR Health Technology Assessment Programme, NHS R&D and the University of Aarhus (Denmark), and provision of equipment from Bio-Rad during the conduct of the study. Outside the submitted work he also reports receiving fees from Novo Nordisk, Astra Zeneca and Napp for speaking at postgraduate education meetings, support to attend a scientific meeting from Napp, and an honorarium and reimbursement of travel expenses from Eli Lilly associated with membership of an independent data monitoring committee for a randomised trial of a medication to lower glucose. No other authors have any competing interests to declare.Clinical TrialN/A.Funding StatementFunding: The Southampton, Cambridge and Oxford Primary Care Departments are members of the NIHR School for Primary Care Research and supported by NIHR Research funds. The University of Cambridge has received salary support in respect of SJG from the NHS in the East of England through the Clinical Academic Reserve. SJG is supported by an MRC Epidemiology Unit programme: MC_UU_12015/4. HDM is an NIHR Clinical Lecturer and supported by an NIHR SPCR grant for this work: SPCR2014-10043. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social CareAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/A - systematic reviewAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are included within the manuscript ie search terms